Skip to content
Parakho

Gland Pharma Ltd

NSE GLANDBSE 543245

Q1 FY27, unaudited

Revenue
₹1,800.27 Cr
Profit after tax
₹316.96 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations1,800.27+19.57%6,430.65
Other income61.23+6.43%316.33
Total income1,861.50+19.09%6,746.98
Employee benefit expense444.00+8.81%1,628.84
Finance costs4.36−62.07%33.28
Depreciation & amortisation111.26+10.10%423.67
Total expenses1,426.52+14.08%5,258.05
Profit before tax434.98+39.09%1,464.58
Tax expense118.02+21.34%437.26
Profit after tax316.96+47.09%1,027.32
Total comprehensive income290.24−27.80%1,458.30
Earnings per share
Earnings per share, basic₹19.23₹62.35
Earnings per share, diluted₹19.22₹62.28

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Gland Pharma reported Q4 FY26 consolidated revenue of INR17,428 million, up 22% year-on-year, with adjusted EBITDA of INR5,244 million at 30% margin and adjusted PAT of INR3,667 million at 21% margin. Full year FY26 revenue grew 14.5% to INR64,307 million, with the CDMO business contributing 46% of total revenue and growing 28%. Management attributed the quarter's performance to new product launches including Dalbavancin, GPO contract wins, capacity utilization improvements and steady contribution from the Cenexi subsidiary in France.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 71 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 23 Aug 2026.